$0.88 EPS Expected for Merck & Co., Inc. (MRK), Northwest Bancshares Has 1.2 Sentiment

July 12, 2017 - By Richard Conner

Northwest Bancshares, Inc. is a savings and loan holding company. The company has market cap of $1.59 billion. The Company’s principal business consists of attracting deposits and making loans secured by various types of collateral, including real estate and other assets in the markets in which it operates. It has a 32.33 P/E ratio. The Company’s divisions include Community Banking and Consumer Finance.

Analysts expect Merck & Co., Inc. (NYSE:MRK) to report $0.88 EPS on July, 28.They anticipate $0.05 EPS change or 5.38% from last quarter’s $0.93 EPS. MRK’s profit would be $2.39B giving it 17.89 P/E if the $0.88 EPS is correct. After having $0.88 EPS previously, Merck & Co., Inc.’s analysts see 0.00% EPS growth. About 2.34M shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 16.86% since July 12, 2016 and is uptrending. It has outperformed by 0.16% the S&P500.

Roof Eidam & Maycock Adv holds 0.96% of its portfolio in Northwest Bancshares, Inc. for 101,915 shares. Minerva Advisors Llc owns 73,625 shares or 0.75% of their US portfolio. Moreover, Denver Investment Advisors Llc has 0.66% invested in the company for 868,311 shares. The Texas-based Carlton Hofferkamp & Jenks Wealth Management Llc has invested 0.6% in the stock. St Germain D J Co Inc, a Massachusetts-based fund reported 223,186 shares.

Ratings analysis reveals 0 of Northwest Bancshares’s analysts are positive. Out of 2 Wall Street analysts rating Northwest Bancshares, 0 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. NWBI was included in 2 notes of analysts from October 26, 2016. The stock of Northwest Bancshares, Inc. (NASDAQ:NWBI) earned “Sell” rating by Sandler O’Neill on Monday, December 19. The stock has “Mkt Perform” rating by FBR Capital on Wednesday, October 26.

Since January 1, 0001, it had 0 insider buys, and 4 sales for $1.54 million activity.

About 92,855 shares traded. Northwest Bancshares, Inc. (NWBI) has risen 6.88% since July 12, 2016 and is uptrending. It has underperformed by 9.82% the S&P500.

Analysts await Northwest Bancshares, Inc. (NASDAQ:NWBI) to report earnings on July, 24. They expect $0.21 EPS, up 5.00% or $0.01 from last year’s $0.2 per share. NWBI’s profit will be $21.38 million for 18.60 P/E if the $0.21 EPS becomes a reality. After $0.17 actual EPS reported by Northwest Bancshares, Inc. for the previous quarter, Wall Street now forecasts 23.53% EPS growth.

Investors sentiment increased to 1.1 in Q4 2016. Its up 0.05, from 1.05 in 2016Q3. It improved, as 66 investors sold Merck & Co., Inc. shares while 603 reduced holdings. 128 funds opened positions while 609 raised stakes. 1.96 billion shares or 0.02% more from 1.96 billion shares in 2016Q3 were reported. The Japan-based Sumitomo Life Insur has invested 0.96% in Merck & Co., Inc. (NYSE:MRK). Moreover, Fulton National Bank & Trust Na has 0.54% invested in Merck & Co., Inc. (NYSE:MRK) for 103,511 shares. Btc Management Incorporated owns 49,844 shares. Summit Finance Wealth Advisors Lc accumulated 12,175 shares. Greylin Mangement holds 4.04% or 286,006 shares in its portfolio. Riverhead Mngmt Limited Liability owns 250,981 shares or 0.91% of their US portfolio. St Germain D J holds 0.05% or 5,802 shares. Town Country Bancorporation Trust Dba First Bankers Trust invested in 2.11% or 64,554 shares. Tocqueville Asset Management L P reported 1.04M shares. National Bank & Trust Pictet & Cie (Asia) Limited has invested 0.69% in Merck & Co., Inc. (NYSE:MRK). Wetherby Asset Mngmt owns 90,472 shares for 1.04% of their portfolio. Provise Management Ltd Liability Corporation invested in 0.38% or 38,118 shares. 621 are held by Lenox Wealth. Wealthtrust Axiom Limited Liability Co holds 1.13% or 52,959 shares. Wheatland Advisors Inc invested in 0.59% or 11,260 shares.

Merck & Co., Inc. is a global healthcare company. The company has market cap of $170.94 billion. The Firm offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It has a 40.35 P/E ratio. It operates through four divisions: Pharmaceutical, Animal Health, Healthcare Services and Alliances.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.